 |
|
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”
Jian Wang, Fei Cao, Chuanwu Zhu, Chao Wu, Rui Huang
Clin Mol Hepatol. 2025;31(2):e140-e142. Published online 2024 Dec 3 DOI: https://doi.org/10.3350/cmh.2024.0960
|
|
Citations to this article as recorded by
 Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TOR
Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin
Clinical and Molecular Hepatology.2025; 31(2): e169. CrossRef
|